BIO Statement on USDA Finalizing Rule for National Bioengineered Food Disclosure Standard

Dec 20 2018
The Biotechnology Innovation Organization today released the following statement in response to USDA issuing a final rule implementing the National Bioengineered Food Disclosure Standard:  

BIO Statement on Hatch-Waxman Integrity Act of 2018

Dec 14 2018
“For almost 40 years, the groundbreaking law known as the Hatch-Waxman Act (HWA) has been highly successful in spurring the development of life-saving new treatments while at the same time vastly broadening the availability of low-cost generic pharmaceuticals."

BIO Applauds Bipartisan 2018 Farm Bill

Dec 11 2018
Biotechnology Innovation Organization (BIO) President & CEO James C. Greenwood today issued the following statement on the 2018 Farm Bill:

BIO Commends Signing of the United States-Mexico-Canada Agreement

Nov 30 2018

Washington, D.C. (November 30, 2018) – Biotechnology Innovation Organization (BIO) President & CEO James C. Greenwood today issued the following statement on the United States-Mexico-Canada...

BIO Statement on EPA Finalizing RFS Volumes for 2019

Nov 30 2018
Brent Erickson, Executive Vice President of the Biotechnology Innovation Organization’s (BIO) Industrial and Environmental Section, released the following statement today on final Renewable Fuel Standard (RFS) volumes for 2019 and the Biomass-Based Diesel Volumes for 2020 published by the Environmental Protection Agency (EPA):

BIO Applauds Inclusion of Pro-Growth Provisions in Tax and Oversight Legislation

Nov 28 2018
“I applaud Chairman Brady and his colleagues on the House Ways & Means Committee for recognizing the unintended consequences faced by far too many small business innovators today due to NOL limitations."

21st Annual BIO CEO & Investor Conference Programming Announced

Nov 28 2018
The Biotechnology Innovation Organization (BIO) today announced preliminary programming for the upcoming BIO CEO & Investor Conference to be held February 11-12, 2019 in New York City. Program lineup covers policy, investment, innovation and patient access. New this year, BIO is offering Executive Leadership courses to help companies develop tools for striking deals and improving corporate reputation. Participants will choose between one of two interactive courses which are based on real-life biopharma experiences and will run on Sunday, February 10.

BIO Statement on Unsubstantiated Reports of Heritable Human Genome Editing Experiments in China

Nov 28 2018
The Biotechnology Innovation Organization (BIO) issued the following statement regarding unsubstantiated reports this week of experiments involving heritable human genome editing in China.

BIO Welcomes 21 New Companies to Industrial & Environmental Section

Nov 28 2018
The Biotechnology Innovation Organization today announced 21 companies have joined the Industrial & Environmental Section over the past year. BIO will work closely with these diverse new members as it continues to lead advocacy efforts that advance the development and adoption of biotechnology into industrial and environmental processes, such as the production of bio-based products and biofuels.

BIO Statement on Proposed Changes to Medicare Advantage and Part D Plans

Nov 26 2018
“Today’s proposed rule to roll back critical protections afforded to some of America’s sickest and most vulnerable Medicare beneficiaries would, if adopted, severely limit seniors’ access to the drugs most appropriate for them, and is yet another unfortunate example of Administration proposals that will financially benefit insurance plans and other middlemen in the drug supply chain at the expense of patients."